中慧生物
Ab&B Bio-Tech

Ab&B Bio-Tech CO., LTD. JS
江蘇中慧元通生物科技股份有限公司
(A joint stock company established in the People's Republic of China with limited liability)
(Stock code: 2627)

INSIDE INFORMATION APPLICATION FOR THE H SHARE FULL CIRCULATION BY THE COMPANY

This announcement is made by Ab&B Bio-Tech CO., LTD. (the "**Company**") pursuant to Rule 13.09(2)(a) of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the "**Listing Rules**") and the Inside Information Provisions under Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).

References are made to the China Securities Regulatory Commission (the "**CSRC**") Announcement [2019] No. 22 "Guidelines on Application for 'Full Circulation' of Domestic Unlisted Shares of H-share Companies" (《H股公司境內未上市股份申請"全流通"業務指引》) issued by the CSRC on November 14, 2019 and amended on August 10, 2023 and the "Trial Administrative Measures for Overseas Securities Offering and Listing by Domestic Companies" (《境內企業境外發行證券和上市管理試行辦法》) issued by the CSRC on February 17, 2023 regarding the guidelines for procedures to apply for full circulation of shares by companies whose H shares are listed on The Stock Exchange of Hong Kong Limited (the "**Stock Exchange**").

The board (the "**Board**") of directors (the "**Directors**") of the Company is pleased to announce that the Company has submitted an application (the "**Application**") to the CSRC on October 15, 2025, in respect of the conversion of 81,661,895 unlisted shares (the "**Unlisted Shares**") into H shares (the "**H Shares**") of the Company and the listing of such shares on the Stock Exchange (the "**H Share Full Circulation**"). Subject to obtaining all the filings and/or approvals from relevant regulatory authorities (including but not limited to the CSRC and the Stock Exchange) and the compliance with all the applicable laws, regulations and rules, such Unlisted Shares shall be converted into H Shares and be eligible to be listed and traded on the Main Board of the Stock Exchange, details of which are as follows:

Name of shareholders	Number of Unlisted Shares to be converted into H Shares	Approximate percentage(1) of the Company's total issued share capital(2)
Jiangsu Tiaoyu Science and Trade Co., Ltd. (江蘇耀宇科貿有限公司)	33,823,083	8.60%
He Yiming (何一鳴)	4,880,176	1.24%
Taizhou Huida Enterprise Management Consulting Service Partnership (Limited Partnership) (泰州慧達企業管理諮詢服務合夥企業(有限合夥))	65,069	0.02%
Jiangsu Jiequan Gaotejia Medical Industry Investment Fund (Limited Partnership) (江蘇疌泉高特佳醫療產業投資基金(有限合夥))	14,854,442	3.78%
Zhuzhou National Innovation Medicine Investment Partnership (Limited Partnership) (株洲市國創新藥投資合夥企業(有限合夥))	6,751,512	1.72%
Pingtan Wenzhou Hangshi Ruihui Investment Partnership (Limited Partnership) (平潭文周杭實瑞慧投資合夥企業(有限合夥))	2,148,335	0.55%
Pingtan Wenzhou Ruixi Investment Partnership (Limited Partnership) (平潭文周瑞璽投資合夥企業(有限合夥))	429,862	0.11%
Zhuzhou Wenzhou Junzhe Venture Capital Partnership (Limited Partnership) (株洲市文周君喆創業投資合夥企業(有限合夥))	428,236	0.11%
Qingdao Yingke Value Venture Capital Partnership (Limited Partnership) (青島盈科價值創業投資合夥企業(有限合夥))	6,445,005	1.64%
Qingdao Yingke Dingxin No. 1 Venture Capital Partnership (Limited Partnership) (青島盈科鼎新一號創業投資合夥企業(有限合夥))	872,250	0.22%
Zibo Yingke Growth No. 2 Venture Capital Partnership (Limited Partnership) (淄博盈科成長二號創業投資合夥企業(有限合夥))	416,767	0.11%

Name of shareholders	Number of Unlisted Shares to be converted into H Shares	Approximate percentage[(1)] of the Company's total issued share capital[(2)]
Anji Aiweidi Enterprise Management Partnership (Limited Partnership) (安吉愛威笛企業管理合夥企業(有限合夥))	4,066,813	1.03%
Shenzhen Songhe Jiyou No. 3 Venture Capital Partnership (Limited Partnership) (深圳市松禾績優三號創業投資合夥企業(有限合夥))	2,148,335	0.55%
Yangzhou Yingdan Equity Investment Partnership (Limited Partnership) (揚州盈丹股權投資合夥企業(有限合夥))	2,057,808	0.52%
Hangzhou Fushi Investment Management Partnership (Limited Partnership) (杭州賦實投資管理合夥企業(有限合夥))	1,672,680	0.43%
Guangxi Guangtou Guohong Health Industry Fund Partnership Enterprise (Limited Partnership) (廣西廣投國宏健康產業基金合夥企業(有限合夥))	601,522	0.15%
Total	**81,661,895**	**20.76%**

Notes:

(1) The percentages have been rounded up to the nearest two decimal places and any discrepancy between the totals and sums of amounts listed in the table is due to rounding.

(2) The calculation is based on the total number of 393,442,600 shares (including 97,080,755 Unlisted Shares and 296,361,845 H Shares) of the Company in issue as of the date of this announcement.

Pursuant to applicable laws and regulations of the People's Republic of China and the articles of association of the Company, no further shareholders' meeting is required to be convened to approve the H Share Full Circulation.

As of the date of this announcement, the Company has not completed the filing with the CSRC in respect of the Application. Further announcement(s) will be made on the progress and details of the Application and the H Share Full Circulation as and when appropriate.

The H Share Full Circulation is subject to other relevant procedures as required by the CSRC, the Stock Exchange and other domestic and overseas regulatory authorities. Shareholders and potential investors of the Company are advised to exercise caution when dealing in the shares of the Company.

By Order of the Board
Ab&B Bio-Tech CO., LTD. JS
Mr. An Youcai
Executive Director, chairman of the Board and general manager

Hong Kong, October 15, 2025

As at the date of this announcement, the Board comprises: (i) Mr. AN Youcai, Ms. LI Runxiang and Mr. HE Yiming as executive Directors; (ii) Mr. CHENG Qianwen, Mr. YU Jianlin and Mr. DU Mu as non-executive Directors; and (iii) Mr. LI Xiangming, Ms. LI Xiaoqing and Mr. CHEN Chengbei as independent non-executive Directors.